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Stevens Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) are rare, life-threatening cutaneous
severe adverse reactions (SCAR) most frequently
induced by a drug hypersensitivity. The clinical manifesta-
tions seem to be related either to a particular group of
drugs, such as antibacterial sulfonamides, anticonvulsant
agents, allopurinol, non-steroidal anti-inflammatory drugs
(NSAIDs), aminopenicillins and quinolones, as well as to
the ethnic/genetic background of the affected individual.
A relevant problem in these subjects is the selection of a
potentially tolerated drug that is less likely to induce a
relapse of the reaction on the basis of cross-reactivity. Aim
of the present study was to analyse a population of 16
patients that were treated in the burn/intensive care
department for a SJS/TEN reaction, and determine the
drugs that were tolerated after the reaction with respect to
the culprit substances. The diagnosis was performed on
the basis of the clinical and histological features according
to the RegiSCAR classification and the first step was with-
drawal of the offending drug. Among the 16 cases, we
found 5 cases of SJS, 8 cases of TEN, and 3 cases of SJS/
TEN overlap. Of the 16, 4 patients were male and 12 were
female, age 14-92 years (average 57.1 years; median 63.5
years). A total of 12 drugs were found as suspected causa-
tive agents. In 3 cases multiple drugs were suspected,
whereas in 13 cases a single drug was implicated. Antimi-
crobials including amoxicillin, levofloxacin, trimethoprim-
sulfamethoxazole, vancomycin (8/16; 50 %) were the most
commonly associated agents followed by antiseizure drugs
(4/16; 25 %), NSAIDs (3/16; 18.75 %), benzodiazepines
(2/16; 12.5 %) and allopurinol (1/16; 6.25 %). The most
common complications noted were secondary infections
(15/16; 93.75 %) and septicemia (11/16; 68.75 %). Mortality
rate was 18,75 % (3/16). Interestingly patients with reac-
tions to quinolones tolerated glycopeptides and carbape-
nems. Also, a patient with reaction to amoxicillin tolerated
carbapenems. One of the 4 patients with reaction to antic-
onvulsant tolerated levetiracetam, 4/4 benzodiazepines,
and 1/4 haloperidol. A patient with suspected reaction to
acetaminophen (amoxicillin was the other involved drug)
tolerated nimesulide and carbapenems. A patient with
reaction to oxcarbazepine tolerated diazepam. We con-
clude that a competent burn centre staff can guarantee the
successful management of the patients.
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